Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV
- Citation:
- Abdallah, I. A., S. F. Hammad, A. Bedair, A. H. Elshafeey, and F. R. Mansour, "Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV", Bioanalysis, vol. 14, no. 4: Newlands Press Ltd, pp. 205 – 216, 2022.
Abstract:
Background: Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection. Aim: This work aimed to develop a new method, using sugaring-out induced homogeneous liquid-liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. Materials & methods: The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent. Results: The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999. Conclusion: These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies. © 2022 Newlands Press.
Notes:
Cited by: 18